Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL

“It was interesting, but also confirmatory, that liso-cel seemed to be safer in terms of cytokine release syndrome and neurotoxicity compared with [axi-cel and liso-cel]. I believe those are really the topline findings, so I'm very excited that we [have shared them] at the 2024 ASH Annual Meeting.”

Andrew Ip, MD, Lymphoma, Hematologic Malignancy, Hackensack University Medical Center, John Theurer Cancer Center, discusses comparative real-world outcomes with commercial CD19-directedCAR T-cell therapies in large B-cell lymphoma (LBCL). Notably, these findings were shared at the 2024 ASH Annual Meeting.

Ip states that he and his colleagues presented compelling findings from a collaborative study across 4centers, including one in Israel and several in the United States, such as Hackensack University Medical Center. The study encompassed 501 patients treated with 1 of the 3 CAR T-cell products that are approved for the treatment of patients with LBCL: tisagenlecleucel (tisa-cel; Kymriah), axicabtagene ciloleucel (axi-cel; Yescarta), and lisocabtagene maraleucel (liso-cel; Breyanzi), he reports. The focus was on evaluating the real-world efficacy and safety of these therapies, Ip shares.

One of the most notable findings, though largely confirmatory, highlights the comparative efficacy of these products in the second-line setting, he continues. Tisa-cel was found to be less effective than axi-cel and liso-cel, with lower progression-free survival and overall survival rates, Ip says. This findingaligns with previously understood data but provides additional validation for the use of CAR T-cell therapy in real-world clinical settings, he emphasizes.

In terms of safety, the findings were similarly confirmatory but just as important, Ip expands. Tisa-cel was associated with a more favorable safety profile, including a lower incidence of cytokine release syndrome and neurotoxicity, compared with both axi-cel and liso-cel, he shares. This safety profile reinforces the potential value of tisa-cel for patients who may be at higher risk for developing these adverse effects, Ip concludes.